FDMT 株価分析 — 4D Molecular Therapeutics Inc (Healthcare >> Biotechnology)
FDMT に関するよくある質問
FDMTのPER(株価収益率)は?
4D Molecular Therapeutics Inc(FDMT)は現在PER 27.19倍で取引されています。
FDMTのROE(自己資本利益率)は?
4D Molecular Therapeutics IncのROEは-35.61%です。
FDMTの配当利回りは?
4D Molecular Therapeutics Incの配当利回りは0.00%です。
FDMTの品質スコア(Quality Score)は?
当社のAIはFDMTの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
FDMTは今が買い時ですか?
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
FDMTはどのセクターに属しますか?
4D Molecular Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
FDMT AI Analysis Summary
Our AI summary for FDMT: 4D Molecular Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 27.19, ROE of -35.61%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 10.26
Price
0.17
(1.68%)
Day Change
|
|
|---|
FDMT, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 10.26 |
| PBV / Sector |
1.17 / 44,022.72
GREAT
|
| Earning Per Share | -3.13 |
| PE / Sector |
27.19 / 19.17
|
| PEG or PE/Growth / Sector |
-3.94 / 1.24
|
| Average 1M Daily Value |
6.92 M
|
| Average 1W Daily Value |
5.15 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
47% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:11 |
| Symbol | FDMT |
| Name | 4D MOLECULAR THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 52.28 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 527.47 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5858 Horton Street, EmeryVille, CA, United States, 94608
Phone: 510 505 2680
Website: https://www.4dmoleculartherapeutics.com
Employees: 196
Sector: Healthcare >> Biotechnology
Description: 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google